Perceptive Advisors
Latest statistics and disclosures from Perceptive Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CERE, FOLD, ACLX, IOVA, NUVL, and represent 32.17% of Perceptive Advisors's stock portfolio.
- Added to shares of these 10 stocks: IOVA (+$53M), ITCI (+$45M), IMTX (+$41M), Contineum Therapeutics (+$28M), MRUS (+$18M), Rapport Therapeutics (+$17M), Inhibrx Biosciences (+$15M), ACRV (+$14M), CGEM (+$13M), INSM (+$12M).
- Started 21 new stock positions in RXRX, Contineum Therapeutics, EGRX, SKYE, BCYC, Tempus Ai, ICLR, Singular Genomics Systems In, BDSX, Inhibrx Biosciences. INSM, MREO, ARGX, FATE, GPCR, FHTX, MRUS, ALLO, SAVA, Rapport Therapeutics, CGEM.
- Reduced shares in these 10 stocks: Inhibrx (-$149M), Fusion Pharmaceuticals (-$146M), MDT (-$74M), SRPT (-$68M), AXSM (-$52M), MDGL (-$46M), ADMA (-$41M), Landos Biopharma (-$32M), IRON (-$31M), TMCI (-$30M).
- Sold out of its positions in ABBV, AGIO, AMLX, AUTL, COGT, Fusion Pharmaceuticals, IBRX, Inhibrx, KURA, Landos Biopharma. MGNX, MLTX, MORF, RAPT, RVMD, SRPT, OMIC, TMCI, ESTA, NAMS.
- Perceptive Advisors was a net seller of stock by $-736M.
- Perceptive Advisors has $4.2B in assets under management (AUM), dropping by -27.36%.
- Central Index Key (CIK): 0001224962
Tip: Access up to 7 years of quarterly data
Positions held by Perceptive Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 109 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cerevel Therapeutics Hldng I (CERE) | 10.6 | $441M | 11M | 40.89 |
|
|
| Amicus Therapeutics (FOLD) | 6.7 | $278M | 28M | 9.92 |
|
|
| Arcellx Common Stock (ACLX) | 5.2 | $215M | 3.9M | 55.19 |
|
|
| Iovance Biotherapeutics (IOVA) | 5.0 | $208M | +34% | 26M | 8.02 |
|
| Nuvalent Inc-a (NUVL) | 4.7 | $193M | -8% | 2.5M | 75.86 |
|
| Rhythm Pharmaceuticals (RYTM) | 3.4 | $142M | +5% | 3.4M | 41.06 |
|
| Vaxcyte (PCVX) | 3.4 | $141M | -3% | 1.9M | 75.51 |
|
| Soleno Therapeutics (SLNO) | 3.1 | $131M | +4% | 3.2M | 40.80 |
|
| Intra Cellular Therapies (ITCI) | 2.8 | $118M | +62% | 1.7M | 68.49 |
|
| Immatics SHS (IMTX) | 2.3 | $94M | +76% | 8.1M | 11.62 |
|
| Neurocrine Biosciences (NBIX) | 2.2 | $90M | -19% | 650k | 137.67 |
|
| Apogee Therapeutics (APGE) | 2.0 | $83M | +2% | 2.1M | 39.35 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.8 | $74M | -38% | 265k | 280.16 |
|
| CryoLife (AORT) | 1.7 | $72M | +4% | 2.8M | 25.65 |
|
| Spyre Therapeutics Com New (SYRE) | 1.7 | $71M | +18% | 3.0M | 23.51 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.6 | $66M | 1.5M | 44.79 |
|
|
| Evolus (EOLS) | 1.5 | $62M | 5.8M | 10.85 |
|
|
| Springworks Therapeutics (SWTX) | 1.5 | $62M | -26% | 1.7M | 37.67 |
|
| Cargo Therapeutics (CRGX) | 1.5 | $61M | +6% | 3.7M | 16.42 |
|
| Astria Therapeutics (ATXS) | 1.4 | $59M | 6.5M | 9.10 |
|
|
| Natera (NTRA) | 1.4 | $57M | -30% | 530k | 108.29 |
|
| Immunovant (IMVT) | 1.4 | $56M | -30% | 2.1M | 26.40 |
|
| Verrica Pharmaceuticals (VRCA) | 1.2 | $52M | 7.1M | 7.29 |
|
|
| Biohaven (BHVN) | 1.2 | $52M | -13% | 1.5M | 34.71 |
|
| Meiragtx Holdings (MGTX) | 1.1 | $48M | 11M | 4.21 |
|
|
| Protagonist Therapeutics (PTGX) | 1.1 | $44M | +27% | 1.3M | 34.65 |
|
| Solid Biosciences Com New (SLDB) | 0.9 | $39M | 6.9M | 5.67 |
|
|
| Celcuity (CELC) | 0.9 | $39M | 2.4M | 16.38 |
|
|
| Medtronic SHS (MDT) | 0.9 | $39M | -65% | 491k | 78.71 |
|
| Viking Therapeutics (VKTX) | 0.9 | $38M | -27% | 721k | 53.01 |
|
| Applied Therapeutics (APLT) | 0.9 | $37M | -5% | 8.0M | 4.67 |
|
| Axsome Therapeutics (AXSM) | 0.9 | $37M | -58% | 459k | 80.50 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.9 | $36M | +27% | 3.9M | 9.03 |
|
| Tarsus Pharmaceuticals (TARS) | 0.8 | $35M | 1.3M | 27.18 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 0.8 | $35M | -35% | 2.4M | 14.46 |
|
| Akero Therapeutics (AKRO) | 0.8 | $35M | +8% | 1.5M | 23.46 |
|
| Edgewise Therapeutics (EWTX) | 0.8 | $33M | -19% | 1.9M | 18.01 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.7 | $31M | +78% | 5.4M | 5.80 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.7 | $31M | -8% | 750k | 41.36 |
|
| Adma Biologics (ADMA) | 0.7 | $31M | -56% | 2.8M | 11.18 |
|
| Bridgebio Pharma (BBIO) | 0.7 | $31M | -13% | 1.2M | 25.33 |
|
| Aldeyra Therapeutics (ALDX) | 0.7 | $31M | +7% | 9.3M | 3.31 |
|
| Nautilus Biotechnology (NAUT) | 0.7 | $30M | 13M | 2.34 |
|
|
| Contineum Therapeutics Cl A | 0.7 | $28M | NEW | 1.6M | 17.61 |
|
| Intuitive Surgical Com New (ISRG) | 0.7 | $28M | -39% | 62k | 444.85 |
|
| Arvinas Ord (ARVN) | 0.7 | $27M | -16% | 1.0M | 26.62 |
|
| Rocket Pharmaceuticals (RCKT) | 0.6 | $27M | -30% | 1.2M | 21.53 |
|
| Disc Medicine (IRON) | 0.6 | $25M | -55% | 553k | 45.07 |
|
| Livanova SHS (LIVN) | 0.6 | $24M | +48% | 444k | 54.82 |
|
| Cg Oncology (CGON) | 0.6 | $23M | -43% | 734k | 31.57 |
|
| Xenon Pharmaceuticals (XENE) | 0.5 | $23M | -34% | 583k | 38.99 |
|
| Ocular Therapeutix (OCUL) | 0.5 | $23M | 3.3M | 6.84 |
|
|
| Pepgen (PEPG) | 0.5 | $23M | 1.4M | 15.96 |
|
|
| Miragen Therapeutics (VRDN) | 0.5 | $21M | -55% | 1.6M | 13.01 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.5 | $21M | 2.5M | 8.15 |
|
|
| Merus N V (MRUS) | 0.4 | $18M | NEW | 300k | 59.17 |
|
| Rapport Therapeutics | 0.4 | $17M | NEW | 748k | 23.26 |
|
| Tyra Biosciences (TYRA) | 0.4 | $16M | +50% | 1.0M | 15.99 |
|
| Inhibrx Biosciences | 0.4 | $15M | NEW | 1.1M | 14.17 |
|
| Arcutis Biotherapeutics (ARQT) | 0.3 | $15M | +107% | 1.6M | 9.30 |
|
| Athira Pharma (ATHA) | 0.3 | $14M | 5.4M | 2.65 |
|
|
| Zymeworks Del (ZYME) | 0.3 | $14M | +55% | 1.7M | 8.51 |
|
| Cullinan Oncology (CGEM) | 0.3 | $13M | NEW | 750k | 17.44 |
|
| Procept Biorobotics Corp (PRCT) | 0.3 | $13M | 211k | 61.09 |
|
|
| Insmed Com Par $.01 (INSM) | 0.3 | $12M | NEW | 180k | 67.00 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.3 | $12M | NEW | 572k | 20.24 |
|
| Icon SHS (ICLR) | 0.2 | $9.8M | NEW | 31k | 313.47 |
|
| Tempus Ai Cl A | 0.2 | $9.6M | NEW | 275k | 35.00 |
|
| Arrivent Biopharma (AVBP) | 0.2 | $7.7M | 415k | 18.55 |
|
|
| Engene Holdings (ENGN) | 0.2 | $7.5M | -19% | 800k | 9.43 |
|
| Silverback Therapeutics (SPRY) | 0.2 | $7.4M | 867k | 8.51 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 0.2 | $6.7M | NEW | 16k | 430.04 |
|
| Allogene Therapeutics (ALLO) | 0.2 | $6.3M | NEW | 2.7M | 2.33 |
|
| Female Health (VERU) | 0.1 | $5.9M | +26% | 7.1M | 0.84 |
|
| Kalvista Pharmaceuticals (KALV) | 0.1 | $5.9M | 500k | 11.78 |
|
|
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.1 | $5.8M | NEW | 769k | 7.50 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.1 | $5.6M | +8% | 640k | 8.70 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.1 | $5.1M | 500k | 10.22 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.1 | $4.5M | NEW | 1.3M | 3.60 |
|
| Cabaletta Bio (CABA) | 0.1 | $4.4M | -65% | 585k | 7.48 |
|
| Precision Biosciences Com New (DTIL) | 0.1 | $4.1M | -11% | 426k | 9.73 |
|
| Skye Bioscience Com New (SKYE) | 0.1 | $4.0M | NEW | 500k | 8.01 |
|
| Trinity Biotech Spons Ard New (TRIB) | 0.1 | $3.8M | 1.8M | 2.13 |
|
|
| Irhythm Technologies (IRTC) | 0.1 | $3.8M | -85% | 35k | 107.64 |
|
| Lyra Therapeutics (LYRA) | 0.1 | $3.5M | 13M | 0.28 |
|
|
| Biodesix (BDSX) | 0.1 | $3.3M | NEW | 2.2M | 1.53 |
|
| Envveno Medical (NVNO) | 0.1 | $3.3M | 623k | 5.25 |
|
|
| Foghorn Therapeutics (FHTX) | 0.1 | $3.1M | NEW | 544k | 5.75 |
|
| Nanobiotix Sponsored Ads (NBTX) | 0.1 | $2.8M | 555k | 5.00 |
|
|
| Cassava Sciences Put Option (SAVA) | 0.1 | $2.3M | NEW | 183k | 12.35 |
|
| Absci Corp (ABSI) | 0.1 | $2.2M | 700k | 3.08 |
|
|
| Spdr Ser Tr S&p Biotech (XBI) | 0.1 | $2.1M | -54% | 23k | 92.71 |
|
| X4 Pharmaceuticals (XFOR) | 0.0 | $2.1M | 3.5M | 0.58 |
|
|
| Forte Biosciences (FBRX) | 0.0 | $1.8M | 3.3M | 0.54 |
|
|
| Revance Therapeutics (RVNC) | 0.0 | $1.5M | 600k | 2.57 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.0 | $1.4M | NEW | 35k | 39.27 |
|
| Novavax Com New Put Option (NVAX) | 0.0 | $1.3M | -85% | 100k | 12.66 |
|
| Fate Therapeutics (FATE) | 0.0 | $1.1M | NEW | 346k | 3.28 |
|
| Kyverna Therapeutics (KYTX) | 0.0 | $1.1M | 150k | 7.50 |
|
|
| Eagle Pharmaceuticals (EGRX) | 0.0 | $971k | NEW | 173k | 5.60 |
|
| Vbi Vaccines Inc Cda Com New (VBIV) | 0.0 | $833k | 1.3M | 0.66 |
|
|
| Tactile Systems Technology, In (TCMD) | 0.0 | $748k | -93% | 63k | 11.94 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.0 | $603k | 117k | 5.16 |
|
|
| Singular Genomics Systems In Com New | 0.0 | $599k | NEW | 71k | 8.45 |
|
| Caremax Cl A New (CMAX) | 0.0 | $342k | 123k | 2.79 |
|
|
| Axogen (AXGN) | 0.0 | $220k | -98% | 30k | 7.24 |
|
| Revolution Medicines *w Exp 12/17/202 (RVMDW) | 0.0 | $26k | 250k | 0.10 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $2.8k | 167k | 0.02 |
|
|
| Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $846.000000 | 60k | 0.01 |
|
Past Filings by Perceptive Advisors
SEC 13F filings are viewable for Perceptive Advisors going back to 2010
- Perceptive Advisors 2024 Q2 restated filed Aug. 16, 2024
- Perceptive Advisors 2024 Q2 filed Aug. 14, 2024
- Perceptive Advisors 2024 Q1 restated filed Aug. 6, 2024
- Perceptive Advisors 2024 Q1 filed May 15, 2024
- Perceptive Advisors 2023 Q4 restated filed Feb. 26, 2024
- Perceptive Advisors 2023 Q4 filed Feb. 14, 2024
- Perceptive Advisors 2023 Q3 filed Nov. 14, 2023
- Perceptive Advisors 2023 Q2 restated filed Aug. 24, 2023
- Perceptive Advisors 2023 Q2 filed Aug. 14, 2023
- Perceptive Advisors 2023 Q1 restated filed May 16, 2023
- Perceptive Advisors 2023 Q1 filed May 15, 2023
- Perceptive Advisors 2022 Q4 filed Feb. 14, 2023
- Perceptive Advisors 2022 Q3 filed Nov. 14, 2022
- Perceptive Advisors 2022 Q2 filed Aug. 15, 2022
- Perceptive Advisors 2022 Q1 filed May 16, 2022
- Perceptive Advisors 2021 Q4 amended filed May 4, 2022